Shengtai Pharmaceutical, Revenue Growth Rates (SGTI), Current and Historic Growth - CSIMarket
CSIMarket
 


Shengtai Pharmaceutical, Inc.  (SGTI)
 

SGTI's Revenue Growth by Quarter and Year

Shengtai Pharmaceutical,'s Revenue results by quarter and year




SGTI Revenue (in millions $) FY 2013 FY 2012 FY 2011 FY 2010
4th Quarter June -
3rd Quarter March 49.72
2nd Quarter December 64.10
1st Quarter September 48.74
FY 162.56





SGTI Revenue third quarter 2013 Y/Y Growth Comment
Shengtai Pharmaceutical, Inc. achieved in the third quarter 2013, above Company average Revenue growth of 24.93% year on year, to $ 49.72 millions.

Looking into third quarter 2013 results within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Revenue growth. While Shengtai Pharmaceutical, Inc.' s Revenue rise of 24.93% ranks overall at the positon no. 1144 in the third quarter 2013.




SGTI Revenue ( Y/Y Growth %) 2013
2012 2011 2010
4th Quarter June - 28.9 % - -
3rd Quarter March 24.93 % -4.53 % - -
2nd Quarter December 49.31 % -12.46 % - -
1st Quarter September 21.67 % 15.65 % - -
FY   - 5.93 % - -

Financial Statements
Shengtai Pharmaceutical,'s third quarter 2013 Revenue $ 49.72 millions SGTI's Income Statement
Shengtai Pharmaceutical,'s third quarter 2012 Revenue $ 39.80 millions Quarterly SGTI's Income Statement


SGTI Revenue (Quarter on Quarter Growth %)

2013
2012 2011 2010
4th Quarter June - 41.31 % 4.65 % -
3rd Quarter March -22.43 % -7.29 % -14.99 % -
2nd Quarter December 31.51 % 7.16 % 41.57 % -
1st Quarter September -13.34 % -8.18 % - -
FY (Year on Year)   - 5.93 % - -




Revenue third quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #145
Overall #1144

Revenue Y/Y Growth Statistics
High Average Low
31.47 % 17.28 % 5.93 %
(Mar 31 2013)   (Jun 30 2012)
Revenue third quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #16
Healthcare Sector #145
Overall #1144
Revenue Y/Y Growth Statistics
High Average Low
31.47 % 17.28 % 5.93 %
(Mar 31 2013)   (Jun 30 2012)

Revenue by Quarter for the Fiscal Years 2010, 2011, 2012, 2013

Shengtai Pharmaceutical,'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
31.51 % 4.54 % -22.43 %
(Dec 31 2012)  


SGTI's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2013 Shengtai Pharmaceutical, Inc. disclosed fall in Revenue from the second quarter by -22.43% to $ 49.72 millions, from $ 64.10 millions achived in the previous reporting period.

But that's not important problem, as Shengtai Pharmaceutical,'s Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 23 other companies have achieved higher Revenue quarter on quarter growth. While Shengtai Pharmaceutical,'s Revenue growth quarter on quarter, overall rank is 2127.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #24
Healthcare Sector #214
Overall #2127
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #24
Healthcare Sector #214
Overall #2127
Revenue Q/Q Growth Statistics
High Average Low
31.51 % 4.54 % -22.43 %
(Dec 31 2012)  


SGTI's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2013 Shengtai Pharmaceutical, Inc. disclosed fall in Revenue from the second quarter by -22.43% to $ 49.72 millions, from $ 64.10 millions achived in the previous reporting period.

But that's not important problem, as Shengtai Pharmaceutical,'s Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 23 other companies have achieved higher Revenue quarter on quarter growth. While Shengtai Pharmaceutical,'s Revenue growth quarter on quarter, overall rank is 2127.


Shengtai Pharmaceutical,'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2013)
12 Months Ending
(Dec 31 2012)
12 Months Ending
(Sep 30 2012)
12 Months Ending
(Jun 30 2012)
12 Months Ending
Cumulative Revenue 12 Months Ending $ 218.81 $ 208.89 $ 187.72 $ 179.03 $ 0.00
Y / Y Revenue Growth (TTM) 31.47 % 24.11 % 7.62 % 5.93 % -
Year on Year Revenue Growth Overall Ranking # 1261 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 4.75 % 11.28 % 4.85 % 7.57 % -
Seq. Revenue Growth (TTM) Overall Ranking # 1144 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 31.47% annual Revenue growth, Shengtai Pharmaceutical, Inc. would report a record annual Revenue rise if the fiscal year would end on Mar 31 2013.

In the Healthcare sector 158 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1261.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 16
Healthcare Sector # 159
Overall # 1261

Revenue TTM Y/Y Growth Statistics
High Average Low
31.47 %
17.28 %
5.93 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 145
S&P 500 # 1144
Cumulative Revenue growth Comment
With 31.47% annual Revenue growth, Shengtai Pharmaceutical, Inc. would report a record annual Revenue rise if the fiscal year would end on Mar 31 2013.

In the Healthcare sector 158 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1261.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 16
Healthcare Sector # 159
Overall # 1261

Revenue TTM Y/Y Growth Statistics
High Average Low
31.47 %
17.28 %
5.93 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 145
S&P 500 # 1144




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SGTI's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Mar 31 2013 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2013
Akorn Inc42.80%$ 42.804 millions
Sangamo Therapeutics Inc 42.60%$ 42.597 millions
Arrowhead Pharmaceuticals Inc 40.00%$ 40.000 millions
Lifevantage Corp39.10%$ 39.099 millions
Soligenix inc 39.08%$ 39.076 millions
Alexion Pharmaceuticals Inc 38.49%$ 38.494 millions
Musclepharm Corporation36.23%$ 36.233 millions
Interpace Biosciences Inc 35.50%$ 35.502 millions
Haemonetics Corporation33.90%$ 33.895 millions
Inspiremd Inc 33.04%$ 33.040 millions
Standard Biotools Inc 32.80%$ 32.800 millions
Cyclo Therapeutics Inc 32.04%$ 32.043 millions
Bio Green Med Solution Inc 31.68%$ 31.677 millions
Seelos Therapeutics inc 30.39%$ 30.393 millions
Hologic Inc30.03%$ 30.032 millions
Pacific Health Care Organization Inc29.90%$ 29.901 millions
Axogen inc 29.61%$ 29.605 millions
Milestone Scientific Inc 29.57%$ 29.570 millions
Merrimack Pharmaceuticals Inc29.19%$ 29.187 millions
Clearpoint Neuro Inc 29.00%$ 29.000 millions
Lifemd Inc 29.00%$ 28.996 millions
Repligen Corp28.32%$ 28.317 millions
Nektar Therapeutics28.16%$ 28.163 millions
Option Care Health Inc 27.91%$ 27.911 millions
Lannett Company Inc27.16%$ 27.158 millions
Nanostring Technologies Inc 26.08%$ 26.077 millions
Icon Plc25.54%$ 25.544 millions
Prophase Labs Inc 25.32%$ 25.324 millions
Icad Inc25.02%$ 25.020 millions
Shengtai Pharmaceutical, Inc.24.92%$ 24.922 millions


About Shengtai Pharmaceutical, Revenue Growth Rates (SGTI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.